WilmerHale has hired corporate partner Sarah Hogan, who specializes in life sciences and digital health licensing transactions, from McDermott Will & Emery in Boston.
Hogan represents companies on complex transactions including the commercialization of pharmaceutical products, patent licensing, software and data transactions, supply and distribution agreements, and joint ventures. Her clients have included start-up companies, venture capital and private-equity backed companies, public companies, hospitals, and research institutions.
She represented Baxalta in a collaboration with Precision BioSciences to develop a cancer therapy, and Innate Pharma SA in its 2015 collaboration with AstraZeneca in the development of an immunotherapy drug.
Hogan said she was not looking to switch firms, but that the move to WilmerHale would allow her to offer her clients a greater depth and breadth of services.
“WilmerHale is a very highly regarded life sciences firm,” Hogan said. “It’s a firm that can really see the whole of the life sciences business from an industry perspective and follow clients more deeply through their life cycle.”
Hogan said her practice would largely remain the same, but that she hopes to bring more digital health within the purview of WilmerHale’s life sciences practice.
“Digital health is gaining ground rapidly in life sciences lately, with more and more biopharma companies interested in the digital space to learn insights about disease, procure information about treatment efficacy, detect and treat disease earlier, and use real-world data and real-world evidence to gain insights for faster deployment of therapies to market,” she said.
Hogan earned a master’s degree in genetics and worked as a scientist at a biotechnology company before deciding to become an attorney.
“I became really interested in the business side, in terms of what was driving what we were doing in the lab,” she said of her decision to switch careers and study law.
Aside from McDermott, Hogan has worked at K&L Gates, Gunderson Dettmer, and Mintz Levin over the course of her career.
“Sarah was a strong contributor and we are sorry to see her go. We wish her well on her future endeavors,” McDermott said in a statement Wednesday.